Top cited articles

Acceptance rate


Time to first decision with review

31 days*

Acceptance to publication

14 days*

Impact Factor




2021 DORIS definition of remission in SLE: final recommendations from an international task force
van Vollenhoven, Ronald F.; Bertsias, George; Doria, Andrea; et al

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
Tummala, Raj; Abreu, Gabriel; Pineda, Lilia; et al

Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years
Ajeganova, Sofia; Hafstrom, Ingiald; Frostegard, Johan

Living with systemic lupus erythematosus in 2020: a European patient survey
Cornet, Alain; Andersen, Jeanette; Myllys, Kirsi; et al

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review
Ugarte-Gil, Manuel Francisco; Mendoza-Pinto, Claudia; Reategui-Sokolova, Cristina; et al

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
Furie, Richard A.; Hough, Douglas R.; Gaudy, Allison; et al

Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies
Ugarte-Gil, Manuel Francisco; Mak, Anselm; Leong, Joanna; et al

Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study
Blazer, Ashira; Dey, Ida Dzifa; Nwaukoni, Janet; et al

Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis
Xiang, Shate; Qu, Yiqian; Qian, Suhai; Wang, Rongyun; et al

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
Northcott, Melissa; Jones, Sarah; Koelmeyer, Rachel; Bonin, Julie; et al

Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis
Helget, Lindsay N.; Dillon, David J.; Wolf, Bethany; et al

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
Sivakumaran, Jagan; Harvey, Paula; Omar, Ahmed; et al

Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus
Zinglersen, Amanda Hempel; Iversen, Katrine Kjaer; Leffers, Henrik Christian Bidstrup; et al

RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
Merola, Joseph F.; Wang, Wenting; Wager, Carrie G.; et al

Phenotypical changes and clinical significance of CD4(+)/CD8(+) T cells in SLE
Yuan, Shiwen; Zeng, Yanting; Li, Jiawei; et al

Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
Balevic, Stephen J.; Weiner, Daniel; Clowse, Megan E. B.; et al

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus
Anderson, Erik W.; Fishbein, Joanna; Hong, Joseph; et al

Absence of renal remission portends poor long-term kidney outcome in lupus nephritis
Pirson, Valerie; Enfrein, Antoine; Houssiau, Frederic A.; Tamirou, Farah

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
Wang, Huijing; Gao, Yunjie; Ma, Yanhong; Cai, Fanghao; et al

Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre
Hill, Deanna D.; Eudy, Amanda M.; Egger, Peter J.; et al